93 related articles for article (PubMed ID: 16135387)
1. Prognostic value of somatostatin receptor subtype 2 expression in colorectal cancer.
Raggi CC; Cianchi F; Valanzano R; Smith MC; Serio M; Maggi M; Orlando C
Regul Pept; 2005 Dec; 132(1-3):23-6. PubMed ID: 16135387
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium -111-pentetreotide.
Orlando C; Raggi CC; Bagnoni L; Sestini R; Briganti V; La Cava G; Bernini G; Tonini GP; Pazzagli M; Serio M; Maggi M
Med Pediatr Oncol; 2001 Jan; 36(1):224-6. PubMed ID: 11464890
[TBL] [Abstract][Full Text] [Related]
3. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer.
Buscail L; Saint-Laurent N; Chastre E; Vaillant JC; Gespach C; Capella G; Kalthoff H; Lluis F; Vaysse N; Susini C
Cancer Res; 1996 Apr; 56(8):1823-7. PubMed ID: 8620499
[TBL] [Abstract][Full Text] [Related]
4. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome.
Raggi CC; Maggi M; Renzi D; Calabrò A; Bagnoni ML; Scaruffi P; Tonini GP; Pazzagli M; De Bernardi B; Bernini G; Serio M; Orlando C
J Clin Endocrinol Metab; 2000 Oct; 85(10):3866-73. PubMed ID: 11061551
[TBL] [Abstract][Full Text] [Related]
5. Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa.
Casini Raggi C; Calabrò A; Renzi D; Briganti V; Cianchi F; Messerini L; Valanzano R; Cameron Smith M; Cortesini C; Tonelli F; Serio M; Maggi M; Orlando C
Clin Cancer Res; 2002 Feb; 8(2):419-27. PubMed ID: 11839658
[TBL] [Abstract][Full Text] [Related]
6. Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction.
Sestini R; Orlando C; Peri A; Tricarico C; Pazzagli M; Serio M; Pagani A; Bussolati G; Granchi S; Maggi M
Clin Cancer Res; 1996 Oct; 2(10):1757-65. PubMed ID: 9816127
[TBL] [Abstract][Full Text] [Related]
7. Type-2 somatostatin receptor mRNA levels in breast and colon cancer determined by a quantitative RT-PCR assay based on dual label fluorogenic probe and the TaqMan technology.
Pinzani P; Orlando C; Raggi CC; Distante V; Valanzano R; Tricarico C; Maggi M; Serio M; Pazzagli M
Regul Pept; 2001 Jun; 99(2-3):79-86. PubMed ID: 11384768
[TBL] [Abstract][Full Text] [Related]
8. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors.
Briganti V; Sestini R; Orlando C; Bernini G; La Cava G; Tamburini A; Raggi CC; Serio M; Maggi M
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2385-91. PubMed ID: 9815638
[TBL] [Abstract][Full Text] [Related]
9. No loss of sst receptors gene expression in advanced stages of colorectal cancer.
Vuaroqueaux V; Dutour A; Briard N; Monges G; Grino M; Oliver C; Ouafik L
Eur J Endocrinol; 1999 Apr; 140(4):362-6. PubMed ID: 10097257
[TBL] [Abstract][Full Text] [Related]
10. Re: Expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer.
Buscail L
J Natl Cancer Inst; 1998 Jun; 90(11):864-5. PubMed ID: 9625179
[No Abstract] [Full Text] [Related]
11. Induction of a negative autocrine loop by expression of sst2 somatostatin receptor in NIH 3T3 cells.
Rauly I; Saint-Laurent N; Delesque N; Buscail L; Estéve JP; Vaysse N; Susini C
J Clin Invest; 1996 Apr; 97(8):1874-83. PubMed ID: 8621771
[TBL] [Abstract][Full Text] [Related]
12. Modulation of pituitary somatostatin receptor subtype (sst1-5) messenger ribonucleic acid levels by changes in the growth hormone axis.
Park S; Kamegai J; Johnson TA; Frohman LA; Kineman RD
Endocrinology; 2000 Oct; 141(10):3556-63. PubMed ID: 11014208
[TBL] [Abstract][Full Text] [Related]
13. [Somatostatin receptors in non-endocrine tumours].
Casini Raggi C; Pinzani P; Gelmini S; Tricarico C; Orlando C; Calabrò A; Renzi D; Cianchi F; Valanzano R; Distante V; Cortesini C; Tonelli F; Cataliotti L; Cameron Smith M; Messerini L; Bianchi S; Pazzagli M; Serio M; Maggi M
Minerva Endocrinol; 2001 Sep; 26(3):149-58. PubMed ID: 11753238
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae.
Laws SA; Gough AC; Evans AA; Bains MA; Primrose JN
Br J Cancer; 1997; 75(3):360-6. PubMed ID: 9020480
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of p53 messenger ribonucleic acid expression in patients after curative resection for stage I to III colorectal cancer: association with colon cancer stem cell markers.
Huh JW; Kim HR; Kim YJ
J Am Coll Surg; 2013 Jun; 216(6):1063-9. PubMed ID: 23571142
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients.
Rosenberg R; Hoos A; Mueller J; Baier P; Stricker D; Werner M; Nekarda H; Siewert JR
J Clin Oncol; 2002 Feb; 20(4):1049-55. PubMed ID: 11844829
[TBL] [Abstract][Full Text] [Related]
17. Transcription of somatostatin receptor subtype 1 and 2 genes in lung cancer.
Thomas F; Brambrilla E; Friedmann A
Lung Cancer; 1994 Jul; 11(1-2):111-4. PubMed ID: 8081701
[No Abstract] [Full Text] [Related]
18. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma.
Gertler R; Rosenberg R; Stricker D; Friederichs J; Hoos A; Werner M; Ulm K; Holzmann B; Nekarda H; Siewert JR
J Clin Oncol; 2004 May; 22(10):1807-14. PubMed ID: 15143073
[TBL] [Abstract][Full Text] [Related]
19. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells.
Dalm VA; van Hagen PM; van Koetsveld PM; Achilefu S; Houtsmuller AB; Pols DH; van der Lely AJ; Lamberts SW; Hofland LJ
Am J Physiol Endocrinol Metab; 2003 Aug; 285(2):E344-53. PubMed ID: 12684217
[TBL] [Abstract][Full Text] [Related]
20. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
